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A rabbit antiserum to the C-terminus of the putative brain amyloid precursor was used to probe Western blots of tissue 
proteins separated by SDS-PAGE. The antiserum specifically labelled a protein of approx. 70 kDa in the Tris buffer- 
soluble fraction of brain samples from rat, Alzheimer subjects, cases of young and old Down’s syndrome, and age- 
matched controls. The 70 kDa protein was present in low concentrations in human liver and kidney, and was undetectable 
in human skeletal muscle. The 70 kDa protein may be a metabolite of the amyloid precursor. 
Amyloid; Antiserum; Western blotting; Alzheimer-type dementia; Down’s syndrome 
1. INTRODUCTION 
In ATD, and in Down’s syndrome cases aged 
>40 years, abnormal protein deposits (amyloid) 
are frequently present in brain plaques and blood 
vessels [11. The amino acid sequence of the amyloid 
peptide (A4) has been determined, and oligo- 
nucleotide probes used to derive the structures of 
possible precursors (see [2]). The processing of 
amyloid precursor proteins (proA4), and the fac- 
tors influencing the liberation of A4, are largely 
unknown. We have, therefore, searched for 
ProA6related proteins in human and rat brain and 
in peripheral tissues using an antiserum to the C- 
terminus of proA4. 
2. MATERIALS AND METHODS 2.3. SDS-PAGE and Western blotting 
Polyacrylamide gradient gels (PAA 4130) and low molecular 
mass protein standards were obtained from Pharmacia (Milton 
Keynes, England). 
Tissue samples containing 30 pg protein [8] or 3 pl protein 
standards were separated in Tris/glycine/SDS buffer [6] by 
SDS-PAGE [9] and electrophoretically transferred to nitro- 
cellulose [6]. 
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2.1. Production of antiserum to the C-terminal 
pentadecapeptide of proA 
The proA peptide HzN-GYENPTYKFFEQMQN-COzH [3] 
was synthesised by the solid-phase method using Fmoc-t-butyl- 
polyamide chemistry [4]. The peptide was coupled to suc- 
cinylated thyroglobulin and an antiserum raised in rabbits [5]. 
2.2. Preparation of tissue samples 
Human autopsy tissues from neuropathologically confirmed 
cases of ATD, Down’s syndrome and age-matched controls 
were stored at - 70°C; rat brain samples were used immediately 
after dissection. Homogenates in Tris buffer were separated by 
centrifugation into soluble and particulate fractions and boiled 
in SDS and 2-mercaptoethanol [6] in preparation for SDS- 
PAGE. Rat cerebral grey matter was rapidly homogenised in the 
presence of SDS and mercaptoethanol, boiled for 5 min, and 
the supernatant separated by centrifugation for 15 min at 
14 000 x g. Extracts of human skeletal muscle were prepared as 
described by Zimmermann et al. [7]. 
2.4. Identification of proAl-related proteins 
Electroblotted nitrocellulose was incubated overnight at 4°C 
with the proA antiserum (diluted 1: lOOO), and reactivity to 
protein bands visualised with biotinylated anti-rabbit Ig (1: 100) 
and streptavidin-biotinylated peroxidase (1: 300) with diamino- 
benzidine as substrate [lo]. The specificity of antibody binding 
to separated proteins was examined using antiserum to which 
proA peptide (300 pg/ml antiserum) had been added, and by 
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use of an antiserum raised to a peptide (somatostatin-14) un- 
related to proA [5]. Protein standards were stained with amido 
black. 
3. RESULTS 
When homogenates of human temporal cortex 
were separated by SDS-PAGE and transferred to 
nitrocellulose, the antiserum to proA stained 
several protein bands including a strongly stained 
band at approx. 70 kDa. The 70 kDa protein was 
not stained by a non-relevant antiserum (section 
2.4). When the proA antiserum was blocked with 
the proA C-terminal pentadecapeptide, labelling 
of the 70 kDa protein was abolished. This 70 kDa 
protein was present in the Tris buffer-soluble frac- 
tion of brain homogenates, but very little was 
detected in the particulate fraction (fig.1). 
No marked differences in the staining intensity 
of the 70 kDa protein in soluble extracts of tem- 
poral cortex were observed, either between groups 
or within groups, of (a) six ATD subjects aged 
65-89 years and six age-matched controls, and (b) 
Down’s syndrome subjects aged 1.5, 27 and 63 
years and controls aged 1.2 and 65 years. The 
70 kDa protein was also present in the soluble frac- 
tion of white matter (corpus callosum) and 
cerebellum from post-mortem human brain, and in 
the hypothalamus and cerebral grey matter of rat 
brain (fig.1). The staining intensity of the 70 kDa 
protein was much lower in the soluble fraction of 
human liver, and even lower in kidney, compared 
with brain. No specific staining was observed in the 
soluble fraction of human skeletal muscle, the par- 
ticulate fractions of human liver, kidney and mus- 
cle, or in plasma from two patients with ATD. 
4. DISCUSSION 
We have demonstrated that an antiserum to the 
C-terminal pentadecapeptide of the putative 
Fig. 1. Labelling of brain proteins on electroblotted nitrocellulose with (A) an antiserum to the proA C-terminus, and (B) antiserum 
blocked with proA C-terminal pentadecapeptide. (a) Temporal cortex, soluble fraction, (b) temporal cortex, particulate fraction, (c) 
corpus callosum, soluble fraction, (d) cerebellum, soluble fraction, (e) rat hypothalamus, homogenate, (f) liver, soluble fraction, (g) 
muscle, soluble fraction, (h) muscle, particulate fraction. 30 pg protein/sample (18.5 fig fore). Molecular mass calibration from experi- 
ment a. 
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amyloid precursor [3] recognizes a soluble protein 
of approx. 70 kDa in post-mortem brain from 
cases of ATD, Down’s syndrome and control sub- 
jects. This protein was probably not a consequence 
of autolysis, because a 70 kDa immunoreactive 
protein was observed in fresh rat brain which was 
rapidly prepared for SDS-PAGE. 
The 70 kDa protein may relate to amyloid in one 
of three ways: (i) Kang et al. [3] isolated a cDNA 
clone encoding a 78.6 kDa protein which contained 
the A4 sequence, and which had characteristics of 
a glycosylated cell-surface receptor. The 70 kDa 
protein may be a product of post-translational pro- 
cessing of the 78.6 kDa protein. (ii) In situ chromo- 
some hybridisation studies using A4 cDNA as 
probe [I l] have indicated that there are several 
chromosomes containing A4-related sequences. 
Our 70 kDa protein may be encoded by a gene car- 
rying the message for a similar, but not identical, 
protein to proA4. (iii) The 70 kDa protein may 
contain an epitope present in proA4, but the 
70 kDa protein may be otherwise unrelated to 
proA4. 
Little information is available concerning brain 
proteins immunoreactive to proA antisera. Using 
antisera to different peptide sequences of proA4, 
Shivers et al. [12] identified a 92 kDa protein 
associated with the plasma membrane of neurons 
in rat brain. In order to investigate the relationship 
of our 70 kDa protein to proA4, we propose to 
peptide-map the 70 kDa protein and compare its 
sequence with the published sequences of proA4. 
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